News
CorMedix to Buy Heron's Drug Portfolio for $145M Cash Plus 14.6M Shares; Heron Keeps $2.3B in Tax Losses and Stays Public
Heron repays its Hercules loan ($93.3M principal) in cash; noteholder Rubric is set to take about half of Heron's 14.6M CorMedix shares at Nov. 6 prices, subject to a price floor.